Global VLP-based Vaccine Market Growth 2026-2032
The global VLP-based Vaccine market size is predicted to grow from US$ 655 million in 2025 to US$ 1164 million in 2032; it is expected to grow at a CAGR of 8.7% from 2026 to 2032.
Virus-like particles (VLPs) have evolved to become a widely accepted technology, especially in the field of vaccinology. In fact, some VLP-based vaccines are currently used as commercial medical products, and other VLP-based products are at different stages of clinical study. Several remarkable advantages have been achieved in the development of VLPs as gene therapy tools and new nanomaterials. In recent years, the technologies develop very fast that are used to characterize the structural integrity, stability, and components, including the encapsidated nucleic acids, of newly synthesized VLPs.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
LP Information, Inc. (LPI) ' newest research report, the “VLP-based Vaccine Industry Forecast” looks at past sales and reviews total world VLP-based Vaccine sales in 2025, providing a comprehensive analysis by region and market sector of projected VLP-based Vaccine sales for 2026 through 2032. With VLP-based Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world VLP-based Vaccine industry.
This Insight Report provides a comprehensive analysis of the global VLP-based Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on VLP-based Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global VLP-based Vaccine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for VLP-based Vaccine and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global VLP-based Vaccine.
This report presents a comprehensive overview, market shares, and growth opportunities of VLP-based Vaccine market by product type, application, key manufacturers and key regions and countries.
Virus-like particles (VLPs) have evolved to become a widely accepted technology, especially in the field of vaccinology. In fact, some VLP-based vaccines are currently used as commercial medical products, and other VLP-based products are at different stages of clinical study. Several remarkable advantages have been achieved in the development of VLPs as gene therapy tools and new nanomaterials. In recent years, the technologies develop very fast that are used to characterize the structural integrity, stability, and components, including the encapsidated nucleic acids, of newly synthesized VLPs.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
LP Information, Inc. (LPI) ' newest research report, the “VLP-based Vaccine Industry Forecast” looks at past sales and reviews total world VLP-based Vaccine sales in 2025, providing a comprehensive analysis by region and market sector of projected VLP-based Vaccine sales for 2026 through 2032. With VLP-based Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world VLP-based Vaccine industry.
This Insight Report provides a comprehensive analysis of the global VLP-based Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on VLP-based Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global VLP-based Vaccine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for VLP-based Vaccine and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global VLP-based Vaccine.
This report presents a comprehensive overview, market shares, and growth opportunities of VLP-based Vaccine market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
- Live-Attenuated Vaccines
- Inactivated Vaccines
- Recombinant Vaccines
- Toxoid Vaccines
Segmentation by Application:
- Hepatitis
- HPV
- Others
This report also splits the market by region:
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Merck and Co.
- GlaxoSmithKline
- Pfizer
- Dynavax Technologies
- Sanofi
- Wantai BioPharm
- Serum Institute of India
- Bharat Biotech
- LG Chem
- VBI Vaccines
Key Questions Addressed in this Report
- What is the 10-year outlook for the global VLP-based Vaccine market?
- What factors are driving VLP-based Vaccine market growth, globally and by region?
- Which technologies are poised for the fastest growth by market and region?
- How do VLP-based Vaccine market opportunities vary by end market size?
- How does VLP-based Vaccine break out by Type, by Application?
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global VLP-based Vaccine Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for VLP-based Vaccine by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for VLP-based Vaccine by Country/Region, 2021, 2025 & 2032
2.2 VLP-based Vaccine Segment by Type
2.2.1 Live-Attenuated Vaccines
2.2.2 Inactivated Vaccines
2.2.3 Recombinant Vaccines
2.2.4 Toxoid Vaccines
2.2.5 VLP-based Vaccine Sales by Type
2.2.5.1 Global VLP-based Vaccine Sales Market Share by Type (2021-2026)
2.2.5.2 Global VLP-based Vaccine Revenue and Market Share by Type (2021-2026)
2.2.5.3 Global VLP-based Vaccine Sale Price by Type (2021-2026)
2.3 VLP-based Vaccine Segment by Application
2.3.1 Hepatitis
2.3.2 HPV
2.3.3 Others
2.3.4 VLP-based Vaccine Sales by Application
2.3.4.1 Global VLP-based Vaccine Sale Market Share by Application (2021-2026)
2.3.4.2 Global VLP-based Vaccine Revenue and Market Share by Application (2021-2026)
2.3.4.3 Global VLP-based Vaccine Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global VLP-based Vaccine Breakdown Data by Company
3.1.1 Global VLP-based Vaccine Annual Sales by Company (2021-2026)
3.1.2 Global VLP-based Vaccine Sales Market Share by Company (2021-2026)
3.2 Global VLP-based Vaccine Annual Revenue by Company (2021-2026)
3.2.1 Global VLP-based Vaccine Revenue by Company (2021-2026)
3.2.2 Global VLP-based Vaccine Revenue Market Share by Company (2021-2026)
3.3 Global VLP-based Vaccine Sale Price by Company
3.4 Key Manufacturers VLP-based Vaccine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers VLP-based Vaccine Product Location Distribution
3.4.2 Players VLP-based Vaccine Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR VLP-BASED VACCINE BY GEOGRAPHIC REGION
4.1 World Historic VLP-based Vaccine Market Size by Geographic Region (2021-2026)
4.1.1 Global VLP-based Vaccine Annual Sales by Geographic Region (2021-2026)
4.1.2 Global VLP-based Vaccine Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic VLP-based Vaccine Market Size by Country/Region (2021-2026)
4.2.1 Global VLP-based Vaccine Annual Sales by Country/Region (2021-2026)
4.2.2 Global VLP-based Vaccine Annual Revenue by Country/Region (2021-2026)
4.3 Americas VLP-based Vaccine Sales Growth
4.4 APAC VLP-based Vaccine Sales Growth
4.5 Europe VLP-based Vaccine Sales Growth
4.6 Middle East & Africa VLP-based Vaccine Sales Growth
5 AMERICAS
5.1 Americas VLP-based Vaccine Sales by Country
5.1.1 Americas VLP-based Vaccine Sales by Country (2021-2026)
5.1.2 Americas VLP-based Vaccine Revenue by Country (2021-2026)
5.2 Americas VLP-based Vaccine Sales by Type (2021-2026)
5.3 Americas VLP-based Vaccine Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC VLP-based Vaccine Sales by Region
6.1.1 APAC VLP-based Vaccine Sales by Region (2021-2026)
6.1.2 APAC VLP-based Vaccine Revenue by Region (2021-2026)
6.2 APAC VLP-based Vaccine Sales by Type (2021-2026)
6.3 APAC VLP-based Vaccine Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe VLP-based Vaccine by Country
7.1.1 Europe VLP-based Vaccine Sales by Country (2021-2026)
7.1.2 Europe VLP-based Vaccine Revenue by Country (2021-2026)
7.2 Europe VLP-based Vaccine Sales by Type (2021-2026)
7.3 Europe VLP-based Vaccine Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa VLP-based Vaccine by Country
8.1.1 Middle East & Africa VLP-based Vaccine Sales by Country (2021-2026)
8.1.2 Middle East & Africa VLP-based Vaccine Revenue by Country (2021-2026)
8.2 Middle East & Africa VLP-based Vaccine Sales by Type (2021-2026)
8.3 Middle East & Africa VLP-based Vaccine Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of VLP-based Vaccine
10.3 Manufacturing Process Analysis of VLP-based Vaccine
10.4 Industry Chain Structure of VLP-based Vaccine
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 VLP-based Vaccine Distributors
11.3 VLP-based Vaccine Customer
12 WORLD FORECAST REVIEW FOR VLP-BASED VACCINE BY GEOGRAPHIC REGION
12.1 Global VLP-based Vaccine Market Size Forecast by Region
12.1.1 Global VLP-based Vaccine Forecast by Region (2027-2032)
12.1.2 Global VLP-based Vaccine Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global VLP-based Vaccine Forecast by Type (2027-2032)
12.7 Global VLP-based Vaccine Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Merck and Co.
13.1.1 Merck and Co. Company Information
13.1.2 Merck and Co. VLP-based Vaccine Product Portfolios and Specifications
13.1.3 Merck and Co. VLP-based Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Merck and Co. Main Business Overview
13.1.5 Merck and Co. Latest Developments
13.2 GlaxoSmithKline
13.2.1 GlaxoSmithKline Company Information
13.2.2 GlaxoSmithKline VLP-based Vaccine Product Portfolios and Specifications
13.2.3 GlaxoSmithKline VLP-based Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 GlaxoSmithKline Main Business Overview
13.2.5 GlaxoSmithKline Latest Developments
13.3 Pfizer
13.3.1 Pfizer Company Information
13.3.2 Pfizer VLP-based Vaccine Product Portfolios and Specifications
13.3.3 Pfizer VLP-based Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Pfizer Main Business Overview
13.3.5 Pfizer Latest Developments
13.4 Dynavax Technologies
13.4.1 Dynavax Technologies Company Information
13.4.2 Dynavax Technologies VLP-based Vaccine Product Portfolios and Specifications
13.4.3 Dynavax Technologies VLP-based Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Dynavax Technologies Main Business Overview
13.4.5 Dynavax Technologies Latest Developments
13.5 Sanofi
13.5.1 Sanofi Company Information
13.5.2 Sanofi VLP-based Vaccine Product Portfolios and Specifications
13.5.3 Sanofi VLP-based Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Sanofi Main Business Overview
13.5.5 Sanofi Latest Developments
13.6 Wantai BioPharm
13.6.1 Wantai BioPharm Company Information
13.6.2 Wantai BioPharm VLP-based Vaccine Product Portfolios and Specifications
13.6.3 Wantai BioPharm VLP-based Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Wantai BioPharm Main Business Overview
13.6.5 Wantai BioPharm Latest Developments
13.7 Serum Institute of India
13.7.1 Serum Institute of India Company Information
13.7.2 Serum Institute of India VLP-based Vaccine Product Portfolios and Specifications
13.7.3 Serum Institute of India VLP-based Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Serum Institute of India Main Business Overview
13.7.5 Serum Institute of India Latest Developments
13.8 Bharat Biotech
13.8.1 Bharat Biotech Company Information
13.8.2 Bharat Biotech VLP-based Vaccine Product Portfolios and Specifications
13.8.3 Bharat Biotech VLP-based Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Bharat Biotech Main Business Overview
13.8.5 Bharat Biotech Latest Developments
13.9 LG Chem
13.9.1 LG Chem Company Information
13.9.2 LG Chem VLP-based Vaccine Product Portfolios and Specifications
13.9.3 LG Chem VLP-based Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 LG Chem Main Business Overview
13.9.5 LG Chem Latest Developments
13.10 VBI Vaccines
13.10.1 VBI Vaccines Company Information
13.10.2 VBI Vaccines VLP-based Vaccine Product Portfolios and Specifications
13.10.3 VBI Vaccines VLP-based Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 VBI Vaccines Main Business Overview
13.10.5 VBI Vaccines Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global VLP-based Vaccine Annual Sales 2021-2032
2.1.2 World Current & Future Analysis for VLP-based Vaccine by Geographic Region, 2021, 2025 & 2032
2.1.3 World Current & Future Analysis for VLP-based Vaccine by Country/Region, 2021, 2025 & 2032
2.2 VLP-based Vaccine Segment by Type
2.2.1 Live-Attenuated Vaccines
2.2.2 Inactivated Vaccines
2.2.3 Recombinant Vaccines
2.2.4 Toxoid Vaccines
2.2.5 VLP-based Vaccine Sales by Type
2.2.5.1 Global VLP-based Vaccine Sales Market Share by Type (2021-2026)
2.2.5.2 Global VLP-based Vaccine Revenue and Market Share by Type (2021-2026)
2.2.5.3 Global VLP-based Vaccine Sale Price by Type (2021-2026)
2.3 VLP-based Vaccine Segment by Application
2.3.1 Hepatitis
2.3.2 HPV
2.3.3 Others
2.3.4 VLP-based Vaccine Sales by Application
2.3.4.1 Global VLP-based Vaccine Sale Market Share by Application (2021-2026)
2.3.4.2 Global VLP-based Vaccine Revenue and Market Share by Application (2021-2026)
2.3.4.3 Global VLP-based Vaccine Sale Price by Application (2021-2026)
3 GLOBAL BY COMPANY
3.1 Global VLP-based Vaccine Breakdown Data by Company
3.1.1 Global VLP-based Vaccine Annual Sales by Company (2021-2026)
3.1.2 Global VLP-based Vaccine Sales Market Share by Company (2021-2026)
3.2 Global VLP-based Vaccine Annual Revenue by Company (2021-2026)
3.2.1 Global VLP-based Vaccine Revenue by Company (2021-2026)
3.2.2 Global VLP-based Vaccine Revenue Market Share by Company (2021-2026)
3.3 Global VLP-based Vaccine Sale Price by Company
3.4 Key Manufacturers VLP-based Vaccine Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers VLP-based Vaccine Product Location Distribution
3.4.2 Players VLP-based Vaccine Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 WORLD HISTORIC REVIEW FOR VLP-BASED VACCINE BY GEOGRAPHIC REGION
4.1 World Historic VLP-based Vaccine Market Size by Geographic Region (2021-2026)
4.1.1 Global VLP-based Vaccine Annual Sales by Geographic Region (2021-2026)
4.1.2 Global VLP-based Vaccine Annual Revenue by Geographic Region (2021-2026)
4.2 World Historic VLP-based Vaccine Market Size by Country/Region (2021-2026)
4.2.1 Global VLP-based Vaccine Annual Sales by Country/Region (2021-2026)
4.2.2 Global VLP-based Vaccine Annual Revenue by Country/Region (2021-2026)
4.3 Americas VLP-based Vaccine Sales Growth
4.4 APAC VLP-based Vaccine Sales Growth
4.5 Europe VLP-based Vaccine Sales Growth
4.6 Middle East & Africa VLP-based Vaccine Sales Growth
5 AMERICAS
5.1 Americas VLP-based Vaccine Sales by Country
5.1.1 Americas VLP-based Vaccine Sales by Country (2021-2026)
5.1.2 Americas VLP-based Vaccine Revenue by Country (2021-2026)
5.2 Americas VLP-based Vaccine Sales by Type (2021-2026)
5.3 Americas VLP-based Vaccine Sales by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC VLP-based Vaccine Sales by Region
6.1.1 APAC VLP-based Vaccine Sales by Region (2021-2026)
6.1.2 APAC VLP-based Vaccine Revenue by Region (2021-2026)
6.2 APAC VLP-based Vaccine Sales by Type (2021-2026)
6.3 APAC VLP-based Vaccine Sales by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 EUROPE
7.1 Europe VLP-based Vaccine by Country
7.1.1 Europe VLP-based Vaccine Sales by Country (2021-2026)
7.1.2 Europe VLP-based Vaccine Revenue by Country (2021-2026)
7.2 Europe VLP-based Vaccine Sales by Type (2021-2026)
7.3 Europe VLP-based Vaccine Sales by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa VLP-based Vaccine by Country
8.1.1 Middle East & Africa VLP-based Vaccine Sales by Country (2021-2026)
8.1.2 Middle East & Africa VLP-based Vaccine Revenue by Country (2021-2026)
8.2 Middle East & Africa VLP-based Vaccine Sales by Type (2021-2026)
8.3 Middle East & Africa VLP-based Vaccine Sales by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 MANUFACTURING COST STRUCTURE ANALYSIS
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of VLP-based Vaccine
10.3 Manufacturing Process Analysis of VLP-based Vaccine
10.4 Industry Chain Structure of VLP-based Vaccine
11 MARKETING, DISTRIBUTORS AND CUSTOMER
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 VLP-based Vaccine Distributors
11.3 VLP-based Vaccine Customer
12 WORLD FORECAST REVIEW FOR VLP-BASED VACCINE BY GEOGRAPHIC REGION
12.1 Global VLP-based Vaccine Market Size Forecast by Region
12.1.1 Global VLP-based Vaccine Forecast by Region (2027-2032)
12.1.2 Global VLP-based Vaccine Annual Revenue Forecast by Region (2027-2032)
12.2 Americas Forecast by Country (2027-2032)
12.3 APAC Forecast by Region (2027-2032)
12.4 Europe Forecast by Country (2027-2032)
12.5 Middle East & Africa Forecast by Country (2027-2032)
12.6 Global VLP-based Vaccine Forecast by Type (2027-2032)
12.7 Global VLP-based Vaccine Forecast by Application (2027-2032)
13 KEY PLAYERS ANALYSIS
13.1 Merck and Co.
13.1.1 Merck and Co. Company Information
13.1.2 Merck and Co. VLP-based Vaccine Product Portfolios and Specifications
13.1.3 Merck and Co. VLP-based Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.1.4 Merck and Co. Main Business Overview
13.1.5 Merck and Co. Latest Developments
13.2 GlaxoSmithKline
13.2.1 GlaxoSmithKline Company Information
13.2.2 GlaxoSmithKline VLP-based Vaccine Product Portfolios and Specifications
13.2.3 GlaxoSmithKline VLP-based Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.2.4 GlaxoSmithKline Main Business Overview
13.2.5 GlaxoSmithKline Latest Developments
13.3 Pfizer
13.3.1 Pfizer Company Information
13.3.2 Pfizer VLP-based Vaccine Product Portfolios and Specifications
13.3.3 Pfizer VLP-based Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.3.4 Pfizer Main Business Overview
13.3.5 Pfizer Latest Developments
13.4 Dynavax Technologies
13.4.1 Dynavax Technologies Company Information
13.4.2 Dynavax Technologies VLP-based Vaccine Product Portfolios and Specifications
13.4.3 Dynavax Technologies VLP-based Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.4.4 Dynavax Technologies Main Business Overview
13.4.5 Dynavax Technologies Latest Developments
13.5 Sanofi
13.5.1 Sanofi Company Information
13.5.2 Sanofi VLP-based Vaccine Product Portfolios and Specifications
13.5.3 Sanofi VLP-based Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.5.4 Sanofi Main Business Overview
13.5.5 Sanofi Latest Developments
13.6 Wantai BioPharm
13.6.1 Wantai BioPharm Company Information
13.6.2 Wantai BioPharm VLP-based Vaccine Product Portfolios and Specifications
13.6.3 Wantai BioPharm VLP-based Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.6.4 Wantai BioPharm Main Business Overview
13.6.5 Wantai BioPharm Latest Developments
13.7 Serum Institute of India
13.7.1 Serum Institute of India Company Information
13.7.2 Serum Institute of India VLP-based Vaccine Product Portfolios and Specifications
13.7.3 Serum Institute of India VLP-based Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.7.4 Serum Institute of India Main Business Overview
13.7.5 Serum Institute of India Latest Developments
13.8 Bharat Biotech
13.8.1 Bharat Biotech Company Information
13.8.2 Bharat Biotech VLP-based Vaccine Product Portfolios and Specifications
13.8.3 Bharat Biotech VLP-based Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.8.4 Bharat Biotech Main Business Overview
13.8.5 Bharat Biotech Latest Developments
13.9 LG Chem
13.9.1 LG Chem Company Information
13.9.2 LG Chem VLP-based Vaccine Product Portfolios and Specifications
13.9.3 LG Chem VLP-based Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.9.4 LG Chem Main Business Overview
13.9.5 LG Chem Latest Developments
13.10 VBI Vaccines
13.10.1 VBI Vaccines Company Information
13.10.2 VBI Vaccines VLP-based Vaccine Product Portfolios and Specifications
13.10.3 VBI Vaccines VLP-based Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
13.10.4 VBI Vaccines Main Business Overview
13.10.5 VBI Vaccines Latest Developments
14 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. VLP-based Vaccine Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. VLP-based Vaccine Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Live-Attenuated Vaccines
Table 4. Major Players of Inactivated Vaccines
Table 5. Major Players of Recombinant Vaccines
Table 6. Major Players of Toxoid Vaccines
Table 7. Global VLP-based Vaccine Sales by Type (2021-2026) & (K Units)
Table 8. Global VLP-based Vaccine Sales Market Share by Type (2021-2026)
Table 9. Global VLP-based Vaccine Revenue by Type (2021-2026) & ($ million)
Table 10. Global VLP-based Vaccine Revenue Market Share by Type (2021-2026)
Table 11. Global VLP-based Vaccine Sale Price by Type (2021-2026) & (US$/Unit)
Table 12. Global VLP-based Vaccine Sale by Application (2021-2026) & (K Units)
Table 13. Global VLP-based Vaccine Sale Market Share by Application (2021-2026)
Table 14. Global VLP-based Vaccine Revenue by Application (2021-2026) & ($ million)
Table 15. Global VLP-based Vaccine Revenue Market Share by Application (2021-2026)
Table 16. Global VLP-based Vaccine Sale Price by Application (2021-2026) & (US$/Unit)
Table 17. Global VLP-based Vaccine Sales by Company (2021-2026) & (K Units)
Table 18. Global VLP-based Vaccine Sales Market Share by Company (2021-2026)
Table 19. Global VLP-based Vaccine Revenue by Company (2021-2026) & ($ millions)
Table 20. Global VLP-based Vaccine Revenue Market Share by Company (2021-2026)
Table 21. Global VLP-based Vaccine Sale Price by Company (2021-2026) & (US$/Unit)
Table 22. Key Manufacturers VLP-based Vaccine Producing Area Distribution and Sales Area
Table 23. Players VLP-based Vaccine Products Offered
Table 24. VLP-based Vaccine Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 25. New Products and Potential Entrants
Table 26. Market M&A Activity & Strategy
Table 27. Global VLP-based Vaccine Sales by Geographic Region (2021-2026) & (K Units)
Table 28. Global VLP-based Vaccine Sales Market Share Geographic Region (2021-2026)
Table 29. Global VLP-based Vaccine Revenue by Geographic Region (2021-2026) & ($ millions)
Table 30. Global VLP-based Vaccine Revenue Market Share by Geographic Region (2021-2026)
Table 31. Global VLP-based Vaccine Sales by Country/Region (2021-2026) & (K Units)
Table 32. Global VLP-based Vaccine Sales Market Share by Country/Region (2021-2026)
Table 33. Global VLP-based Vaccine Revenue by Country/Region (2021-2026) & ($ millions)
Table 34. Global VLP-based Vaccine Revenue Market Share by Country/Region (2021-2026)
Table 35. Americas VLP-based Vaccine Sales by Country (2021-2026) & (K Units)
Table 36. Americas VLP-based Vaccine Sales Market Share by Country (2021-2026)
Table 37. Americas VLP-based Vaccine Revenue by Country (2021-2026) & ($ millions)
Table 38. Americas VLP-based Vaccine Sales by Type (2021-2026) & (K Units)
Table 39. Americas VLP-based Vaccine Sales by Application (2021-2026) & (K Units)
Table 40. APAC VLP-based Vaccine Sales by Region (2021-2026) & (K Units)
Table 41. APAC VLP-based Vaccine Sales Market Share by Region (2021-2026)
Table 42. APAC VLP-based Vaccine Revenue by Region (2021-2026) & ($ millions)
Table 43. APAC VLP-based Vaccine Sales by Type (2021-2026) & (K Units)
Table 44. APAC VLP-based Vaccine Sales by Application (2021-2026) & (K Units)
Table 45. Europe VLP-based Vaccine Sales by Country (2021-2026) & (K Units)
Table 46. Europe VLP-based Vaccine Revenue by Country (2021-2026) & ($ millions)
Table 47. Europe VLP-based Vaccine Sales by Type (2021-2026) & (K Units)
Table 48. Europe VLP-based Vaccine Sales by Application (2021-2026) & (K Units)
Table 49. Middle East & Africa VLP-based Vaccine Sales by Country (2021-2026) & (K Units)
Table 50. Middle East & Africa VLP-based Vaccine Revenue Market Share by Country (2021-2026)
Table 51. Middle East & Africa VLP-based Vaccine Sales by Type (2021-2026) & (K Units)
Table 52. Middle East & Africa VLP-based Vaccine Sales by Application (2021-2026) & (K Units)
Table 53. Key Market Drivers & Growth Opportunities of VLP-based Vaccine
Table 54. Key Market Challenges & Risks of VLP-based Vaccine
Table 55. Key Industry Trends of VLP-based Vaccine
Table 56. VLP-based Vaccine Raw Material
Table 57. Key Suppliers of Raw Materials
Table 58. VLP-based Vaccine Distributors List
Table 59. VLP-based Vaccine Customer List
Table 60. Global VLP-based Vaccine Sales Forecast by Region (2027-2032) & (K Units)
Table 61. Global VLP-based Vaccine Revenue Forecast by Region (2027-2032) & ($ millions)
Table 62. Americas VLP-based Vaccine Sales Forecast by Country (2027-2032) & (K Units)
Table 63. Americas VLP-based Vaccine Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 64. APAC VLP-based Vaccine Sales Forecast by Region (2027-2032) & (K Units)
Table 65. APAC VLP-based Vaccine Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 66. Europe VLP-based Vaccine Sales Forecast by Country (2027-2032) & (K Units)
Table 67. Europe VLP-based Vaccine Revenue Forecast by Country (2027-2032) & ($ millions)
Table 68. Middle East & Africa VLP-based Vaccine Sales Forecast by Country (2027-2032) & (K Units)
Table 69. Middle East & Africa VLP-based Vaccine Revenue Forecast by Country (2027-2032) & ($ millions)
Table 70. Global VLP-based Vaccine Sales Forecast by Type (2027-2032) & (K Units)
Table 71. Global VLP-based Vaccine Revenue Forecast by Type (2027-2032) & ($ millions)
Table 72. Global VLP-based Vaccine Sales Forecast by Application (2027-2032) & (K Units)
Table 73. Global VLP-based Vaccine Revenue Forecast by Application (2027-2032) & ($ millions)
Table 74. Merck and Co. Basic Information, VLP-based Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 75. Merck and Co. VLP-based Vaccine Product Portfolios and Specifications
Table 76. Merck and Co. VLP-based Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 77. Merck and Co. Main Business
Table 78. Merck and Co. Latest Developments
Table 79. GlaxoSmithKline Basic Information, VLP-based Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 80. GlaxoSmithKline VLP-based Vaccine Product Portfolios and Specifications
Table 81. GlaxoSmithKline VLP-based Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 82. GlaxoSmithKline Main Business
Table 83. GlaxoSmithKline Latest Developments
Table 84. Pfizer Basic Information, VLP-based Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 85. Pfizer VLP-based Vaccine Product Portfolios and Specifications
Table 86. Pfizer VLP-based Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 87. Pfizer Main Business
Table 88. Pfizer Latest Developments
Table 89. Dynavax Technologies Basic Information, VLP-based Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 90. Dynavax Technologies VLP-based Vaccine Product Portfolios and Specifications
Table 91. Dynavax Technologies VLP-based Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 92. Dynavax Technologies Main Business
Table 93. Dynavax Technologies Latest Developments
Table 94. Sanofi Basic Information, VLP-based Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 95. Sanofi VLP-based Vaccine Product Portfolios and Specifications
Table 96. Sanofi VLP-based Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 97. Sanofi Main Business
Table 98. Sanofi Latest Developments
Table 99. Wantai BioPharm Basic Information, VLP-based Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 100. Wantai BioPharm VLP-based Vaccine Product Portfolios and Specifications
Table 101. Wantai BioPharm VLP-based Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 102. Wantai BioPharm Main Business
Table 103. Wantai BioPharm Latest Developments
Table 104. Serum Institute of India Basic Information, VLP-based Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 105. Serum Institute of India VLP-based Vaccine Product Portfolios and Specifications
Table 106. Serum Institute of India VLP-based Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 107. Serum Institute of India Main Business
Table 108. Serum Institute of India Latest Developments
Table 109. Bharat Biotech Basic Information, VLP-based Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 110. Bharat Biotech VLP-based Vaccine Product Portfolios and Specifications
Table 111. Bharat Biotech VLP-based Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 112. Bharat Biotech Main Business
Table 113. Bharat Biotech Latest Developments
Table 114. LG Chem Basic Information, VLP-based Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 115. LG Chem VLP-based Vaccine Product Portfolios and Specifications
Table 116. LG Chem VLP-based Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 117. LG Chem Main Business
Table 118. LG Chem Latest Developments
Table 119. VBI Vaccines Basic Information, VLP-based Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 120. VBI Vaccines VLP-based Vaccine Product Portfolios and Specifications
Table 121. VBI Vaccines VLP-based Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 122. VBI Vaccines Main Business
Table 123. VBI Vaccines Latest Developments
Table 1. VLP-based Vaccine Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & ($ millions)
Table 2. VLP-based Vaccine Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Live-Attenuated Vaccines
Table 4. Major Players of Inactivated Vaccines
Table 5. Major Players of Recombinant Vaccines
Table 6. Major Players of Toxoid Vaccines
Table 7. Global VLP-based Vaccine Sales by Type (2021-2026) & (K Units)
Table 8. Global VLP-based Vaccine Sales Market Share by Type (2021-2026)
Table 9. Global VLP-based Vaccine Revenue by Type (2021-2026) & ($ million)
Table 10. Global VLP-based Vaccine Revenue Market Share by Type (2021-2026)
Table 11. Global VLP-based Vaccine Sale Price by Type (2021-2026) & (US$/Unit)
Table 12. Global VLP-based Vaccine Sale by Application (2021-2026) & (K Units)
Table 13. Global VLP-based Vaccine Sale Market Share by Application (2021-2026)
Table 14. Global VLP-based Vaccine Revenue by Application (2021-2026) & ($ million)
Table 15. Global VLP-based Vaccine Revenue Market Share by Application (2021-2026)
Table 16. Global VLP-based Vaccine Sale Price by Application (2021-2026) & (US$/Unit)
Table 17. Global VLP-based Vaccine Sales by Company (2021-2026) & (K Units)
Table 18. Global VLP-based Vaccine Sales Market Share by Company (2021-2026)
Table 19. Global VLP-based Vaccine Revenue by Company (2021-2026) & ($ millions)
Table 20. Global VLP-based Vaccine Revenue Market Share by Company (2021-2026)
Table 21. Global VLP-based Vaccine Sale Price by Company (2021-2026) & (US$/Unit)
Table 22. Key Manufacturers VLP-based Vaccine Producing Area Distribution and Sales Area
Table 23. Players VLP-based Vaccine Products Offered
Table 24. VLP-based Vaccine Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 25. New Products and Potential Entrants
Table 26. Market M&A Activity & Strategy
Table 27. Global VLP-based Vaccine Sales by Geographic Region (2021-2026) & (K Units)
Table 28. Global VLP-based Vaccine Sales Market Share Geographic Region (2021-2026)
Table 29. Global VLP-based Vaccine Revenue by Geographic Region (2021-2026) & ($ millions)
Table 30. Global VLP-based Vaccine Revenue Market Share by Geographic Region (2021-2026)
Table 31. Global VLP-based Vaccine Sales by Country/Region (2021-2026) & (K Units)
Table 32. Global VLP-based Vaccine Sales Market Share by Country/Region (2021-2026)
Table 33. Global VLP-based Vaccine Revenue by Country/Region (2021-2026) & ($ millions)
Table 34. Global VLP-based Vaccine Revenue Market Share by Country/Region (2021-2026)
Table 35. Americas VLP-based Vaccine Sales by Country (2021-2026) & (K Units)
Table 36. Americas VLP-based Vaccine Sales Market Share by Country (2021-2026)
Table 37. Americas VLP-based Vaccine Revenue by Country (2021-2026) & ($ millions)
Table 38. Americas VLP-based Vaccine Sales by Type (2021-2026) & (K Units)
Table 39. Americas VLP-based Vaccine Sales by Application (2021-2026) & (K Units)
Table 40. APAC VLP-based Vaccine Sales by Region (2021-2026) & (K Units)
Table 41. APAC VLP-based Vaccine Sales Market Share by Region (2021-2026)
Table 42. APAC VLP-based Vaccine Revenue by Region (2021-2026) & ($ millions)
Table 43. APAC VLP-based Vaccine Sales by Type (2021-2026) & (K Units)
Table 44. APAC VLP-based Vaccine Sales by Application (2021-2026) & (K Units)
Table 45. Europe VLP-based Vaccine Sales by Country (2021-2026) & (K Units)
Table 46. Europe VLP-based Vaccine Revenue by Country (2021-2026) & ($ millions)
Table 47. Europe VLP-based Vaccine Sales by Type (2021-2026) & (K Units)
Table 48. Europe VLP-based Vaccine Sales by Application (2021-2026) & (K Units)
Table 49. Middle East & Africa VLP-based Vaccine Sales by Country (2021-2026) & (K Units)
Table 50. Middle East & Africa VLP-based Vaccine Revenue Market Share by Country (2021-2026)
Table 51. Middle East & Africa VLP-based Vaccine Sales by Type (2021-2026) & (K Units)
Table 52. Middle East & Africa VLP-based Vaccine Sales by Application (2021-2026) & (K Units)
Table 53. Key Market Drivers & Growth Opportunities of VLP-based Vaccine
Table 54. Key Market Challenges & Risks of VLP-based Vaccine
Table 55. Key Industry Trends of VLP-based Vaccine
Table 56. VLP-based Vaccine Raw Material
Table 57. Key Suppliers of Raw Materials
Table 58. VLP-based Vaccine Distributors List
Table 59. VLP-based Vaccine Customer List
Table 60. Global VLP-based Vaccine Sales Forecast by Region (2027-2032) & (K Units)
Table 61. Global VLP-based Vaccine Revenue Forecast by Region (2027-2032) & ($ millions)
Table 62. Americas VLP-based Vaccine Sales Forecast by Country (2027-2032) & (K Units)
Table 63. Americas VLP-based Vaccine Annual Revenue Forecast by Country (2027-2032) & ($ millions)
Table 64. APAC VLP-based Vaccine Sales Forecast by Region (2027-2032) & (K Units)
Table 65. APAC VLP-based Vaccine Annual Revenue Forecast by Region (2027-2032) & ($ millions)
Table 66. Europe VLP-based Vaccine Sales Forecast by Country (2027-2032) & (K Units)
Table 67. Europe VLP-based Vaccine Revenue Forecast by Country (2027-2032) & ($ millions)
Table 68. Middle East & Africa VLP-based Vaccine Sales Forecast by Country (2027-2032) & (K Units)
Table 69. Middle East & Africa VLP-based Vaccine Revenue Forecast by Country (2027-2032) & ($ millions)
Table 70. Global VLP-based Vaccine Sales Forecast by Type (2027-2032) & (K Units)
Table 71. Global VLP-based Vaccine Revenue Forecast by Type (2027-2032) & ($ millions)
Table 72. Global VLP-based Vaccine Sales Forecast by Application (2027-2032) & (K Units)
Table 73. Global VLP-based Vaccine Revenue Forecast by Application (2027-2032) & ($ millions)
Table 74. Merck and Co. Basic Information, VLP-based Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 75. Merck and Co. VLP-based Vaccine Product Portfolios and Specifications
Table 76. Merck and Co. VLP-based Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 77. Merck and Co. Main Business
Table 78. Merck and Co. Latest Developments
Table 79. GlaxoSmithKline Basic Information, VLP-based Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 80. GlaxoSmithKline VLP-based Vaccine Product Portfolios and Specifications
Table 81. GlaxoSmithKline VLP-based Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 82. GlaxoSmithKline Main Business
Table 83. GlaxoSmithKline Latest Developments
Table 84. Pfizer Basic Information, VLP-based Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 85. Pfizer VLP-based Vaccine Product Portfolios and Specifications
Table 86. Pfizer VLP-based Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 87. Pfizer Main Business
Table 88. Pfizer Latest Developments
Table 89. Dynavax Technologies Basic Information, VLP-based Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 90. Dynavax Technologies VLP-based Vaccine Product Portfolios and Specifications
Table 91. Dynavax Technologies VLP-based Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 92. Dynavax Technologies Main Business
Table 93. Dynavax Technologies Latest Developments
Table 94. Sanofi Basic Information, VLP-based Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 95. Sanofi VLP-based Vaccine Product Portfolios and Specifications
Table 96. Sanofi VLP-based Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 97. Sanofi Main Business
Table 98. Sanofi Latest Developments
Table 99. Wantai BioPharm Basic Information, VLP-based Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 100. Wantai BioPharm VLP-based Vaccine Product Portfolios and Specifications
Table 101. Wantai BioPharm VLP-based Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 102. Wantai BioPharm Main Business
Table 103. Wantai BioPharm Latest Developments
Table 104. Serum Institute of India Basic Information, VLP-based Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 105. Serum Institute of India VLP-based Vaccine Product Portfolios and Specifications
Table 106. Serum Institute of India VLP-based Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 107. Serum Institute of India Main Business
Table 108. Serum Institute of India Latest Developments
Table 109. Bharat Biotech Basic Information, VLP-based Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 110. Bharat Biotech VLP-based Vaccine Product Portfolios and Specifications
Table 111. Bharat Biotech VLP-based Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 112. Bharat Biotech Main Business
Table 113. Bharat Biotech Latest Developments
Table 114. LG Chem Basic Information, VLP-based Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 115. LG Chem VLP-based Vaccine Product Portfolios and Specifications
Table 116. LG Chem VLP-based Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 117. LG Chem Main Business
Table 118. LG Chem Latest Developments
Table 119. VBI Vaccines Basic Information, VLP-based Vaccine Manufacturing Base, Sales Area and Its Competitors
Table 120. VBI Vaccines VLP-based Vaccine Product Portfolios and Specifications
Table 121. VBI Vaccines VLP-based Vaccine Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 122. VBI Vaccines Main Business
Table 123. VBI Vaccines Latest Developments
LIST OF FIGURES
Figure 1. Picture of VLP-based Vaccine
Figure 2. VLP-based Vaccine Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global VLP-based Vaccine Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global VLP-based Vaccine Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. VLP-based Vaccine Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. VLP-based Vaccine Sales Market Share by Country/Region (2025)
Figure 10. VLP-based Vaccine Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Live-Attenuated Vaccines
Figure 12. Product Picture of Inactivated Vaccines
Figure 13. Product Picture of Recombinant Vaccines
Figure 14. Product Picture of Toxoid Vaccines
Figure 15. Global VLP-based Vaccine Sales Market Share by Type in 2026
Figure 16. Global VLP-based Vaccine Revenue Market Share by Type (2021-2026)
Figure 17. VLP-based Vaccine Consumed in Hepatitis
Figure 18. Global VLP-based Vaccine Market: Hepatitis (2021-2026) & (K Units)
Figure 19. VLP-based Vaccine Consumed in HPV
Figure 20. Global VLP-based Vaccine Market: HPV (2021-2026) & (K Units)
Figure 21. VLP-based Vaccine Consumed in Others
Figure 22. Global VLP-based Vaccine Market: Others (2021-2026) & (K Units)
Figure 23. Global VLP-based Vaccine Sale Market Share by Application (2025)
Figure 24. Global VLP-based Vaccine Revenue Market Share by Application in 2026
Figure 25. VLP-based Vaccine Sales by Company in 2026 (K Units)
Figure 26. Global VLP-based Vaccine Sales Market Share by Company in 2026
Figure 27. VLP-based Vaccine Revenue by Company in 2026 ($ millions)
Figure 28. Global VLP-based Vaccine Revenue Market Share by Company in 2026
Figure 29. Global VLP-based Vaccine Sales Market Share by Geographic Region (2021-2026)
Figure 30. Global VLP-based Vaccine Revenue Market Share by Geographic Region in 2026
Figure 31. Americas VLP-based Vaccine Sales 2021-2026 (K Units)
Figure 32. Americas VLP-based Vaccine Revenue 2021-2026 ($ millions)
Figure 33. APAC VLP-based Vaccine Sales 2021-2026 (K Units)
Figure 34. APAC VLP-based Vaccine Revenue 2021-2026 ($ millions)
Figure 35. Europe VLP-based Vaccine Sales 2021-2026 (K Units)
Figure 36. Europe VLP-based Vaccine Revenue 2021-2026 ($ millions)
Figure 37. Middle East & Africa VLP-based Vaccine Sales 2021-2026 (K Units)
Figure 38. Middle East & Africa VLP-based Vaccine Revenue 2021-2026 ($ millions)
Figure 39. Americas VLP-based Vaccine Sales Market Share by Country in 2026
Figure 40. Americas VLP-based Vaccine Revenue Market Share by Country (2021-2026)
Figure 41. Americas VLP-based Vaccine Sales Market Share by Type (2021-2026)
Figure 42. Americas VLP-based Vaccine Sales Market Share by Application (2021-2026)
Figure 43. United States VLP-based Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 44. Canada VLP-based Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 45. Mexico VLP-based Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 46. Brazil VLP-based Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 47. APAC VLP-based Vaccine Sales Market Share by Region in 2026
Figure 48. APAC VLP-based Vaccine Revenue Market Share by Region (2021-2026)
Figure 49. APAC VLP-based Vaccine Sales Market Share by Type (2021-2026)
Figure 50. APAC VLP-based Vaccine Sales Market Share by Application (2021-2026)
Figure 51. China VLP-based Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 52. Japan VLP-based Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 53. South Korea VLP-based Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 54. Southeast Asia VLP-based Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 55. India VLP-based Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 56. Australia VLP-based Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 57. China Taiwan VLP-based Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 58. Europe VLP-based Vaccine Sales Market Share by Country in 2026
Figure 59. Europe VLP-based Vaccine Revenue Market Share by Country (2021-2026)
Figure 60. Europe VLP-based Vaccine Sales Market Share by Type (2021-2026)
Figure 61. Europe VLP-based Vaccine Sales Market Share by Application (2021-2026)
Figure 62. Germany VLP-based Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 63. France VLP-based Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 64. UK VLP-based Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 65. Italy VLP-based Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 66. Russia VLP-based Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 67. Middle East & Africa VLP-based Vaccine Sales Market Share by Country (2021-2026)
Figure 68. Middle East & Africa VLP-based Vaccine Sales Market Share by Type (2021-2026)
Figure 69. Middle East & Africa VLP-based Vaccine Sales Market Share by Application (2021-2026)
Figure 70. Egypt VLP-based Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 71. South Africa VLP-based Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 72. Israel VLP-based Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 73. Turkey VLP-based Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 74. GCC Countries VLP-based Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 75. Manufacturing Cost Structure Analysis of VLP-based Vaccine in 2026
Figure 76. Manufacturing Process Analysis of VLP-based Vaccine
Figure 77. Industry Chain Structure of VLP-based Vaccine
Figure 78. Channels of Distribution
Figure 79. Global VLP-based Vaccine Sales Market Forecast by Region (2027-2032)
Figure 80. Global VLP-based Vaccine Revenue Market Share Forecast by Region (2027-2032)
Figure 81. Global VLP-based Vaccine Sales Market Share Forecast by Type (2027-2032)
Figure 82. Global VLP-based Vaccine Revenue Market Share Forecast by Type (2027-2032)
Figure 83. Global VLP-based Vaccine Sales Market Share Forecast by Application (2027-2032)
Figure 84. Global VLP-based Vaccine Revenue Market Share Forecast by Application (2027-2032)
Figure 1. Picture of VLP-based Vaccine
Figure 2. VLP-based Vaccine Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global VLP-based Vaccine Sales Growth Rate 2021-2032 (K Units)
Figure 7. Global VLP-based Vaccine Revenue Growth Rate 2021-2032 ($ millions)
Figure 8. VLP-based Vaccine Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 9. VLP-based Vaccine Sales Market Share by Country/Region (2025)
Figure 10. VLP-based Vaccine Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 11. Product Picture of Live-Attenuated Vaccines
Figure 12. Product Picture of Inactivated Vaccines
Figure 13. Product Picture of Recombinant Vaccines
Figure 14. Product Picture of Toxoid Vaccines
Figure 15. Global VLP-based Vaccine Sales Market Share by Type in 2026
Figure 16. Global VLP-based Vaccine Revenue Market Share by Type (2021-2026)
Figure 17. VLP-based Vaccine Consumed in Hepatitis
Figure 18. Global VLP-based Vaccine Market: Hepatitis (2021-2026) & (K Units)
Figure 19. VLP-based Vaccine Consumed in HPV
Figure 20. Global VLP-based Vaccine Market: HPV (2021-2026) & (K Units)
Figure 21. VLP-based Vaccine Consumed in Others
Figure 22. Global VLP-based Vaccine Market: Others (2021-2026) & (K Units)
Figure 23. Global VLP-based Vaccine Sale Market Share by Application (2025)
Figure 24. Global VLP-based Vaccine Revenue Market Share by Application in 2026
Figure 25. VLP-based Vaccine Sales by Company in 2026 (K Units)
Figure 26. Global VLP-based Vaccine Sales Market Share by Company in 2026
Figure 27. VLP-based Vaccine Revenue by Company in 2026 ($ millions)
Figure 28. Global VLP-based Vaccine Revenue Market Share by Company in 2026
Figure 29. Global VLP-based Vaccine Sales Market Share by Geographic Region (2021-2026)
Figure 30. Global VLP-based Vaccine Revenue Market Share by Geographic Region in 2026
Figure 31. Americas VLP-based Vaccine Sales 2021-2026 (K Units)
Figure 32. Americas VLP-based Vaccine Revenue 2021-2026 ($ millions)
Figure 33. APAC VLP-based Vaccine Sales 2021-2026 (K Units)
Figure 34. APAC VLP-based Vaccine Revenue 2021-2026 ($ millions)
Figure 35. Europe VLP-based Vaccine Sales 2021-2026 (K Units)
Figure 36. Europe VLP-based Vaccine Revenue 2021-2026 ($ millions)
Figure 37. Middle East & Africa VLP-based Vaccine Sales 2021-2026 (K Units)
Figure 38. Middle East & Africa VLP-based Vaccine Revenue 2021-2026 ($ millions)
Figure 39. Americas VLP-based Vaccine Sales Market Share by Country in 2026
Figure 40. Americas VLP-based Vaccine Revenue Market Share by Country (2021-2026)
Figure 41. Americas VLP-based Vaccine Sales Market Share by Type (2021-2026)
Figure 42. Americas VLP-based Vaccine Sales Market Share by Application (2021-2026)
Figure 43. United States VLP-based Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 44. Canada VLP-based Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 45. Mexico VLP-based Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 46. Brazil VLP-based Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 47. APAC VLP-based Vaccine Sales Market Share by Region in 2026
Figure 48. APAC VLP-based Vaccine Revenue Market Share by Region (2021-2026)
Figure 49. APAC VLP-based Vaccine Sales Market Share by Type (2021-2026)
Figure 50. APAC VLP-based Vaccine Sales Market Share by Application (2021-2026)
Figure 51. China VLP-based Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 52. Japan VLP-based Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 53. South Korea VLP-based Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 54. Southeast Asia VLP-based Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 55. India VLP-based Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 56. Australia VLP-based Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 57. China Taiwan VLP-based Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 58. Europe VLP-based Vaccine Sales Market Share by Country in 2026
Figure 59. Europe VLP-based Vaccine Revenue Market Share by Country (2021-2026)
Figure 60. Europe VLP-based Vaccine Sales Market Share by Type (2021-2026)
Figure 61. Europe VLP-based Vaccine Sales Market Share by Application (2021-2026)
Figure 62. Germany VLP-based Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 63. France VLP-based Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 64. UK VLP-based Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 65. Italy VLP-based Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 66. Russia VLP-based Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 67. Middle East & Africa VLP-based Vaccine Sales Market Share by Country (2021-2026)
Figure 68. Middle East & Africa VLP-based Vaccine Sales Market Share by Type (2021-2026)
Figure 69. Middle East & Africa VLP-based Vaccine Sales Market Share by Application (2021-2026)
Figure 70. Egypt VLP-based Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 71. South Africa VLP-based Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 72. Israel VLP-based Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 73. Turkey VLP-based Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 74. GCC Countries VLP-based Vaccine Revenue Growth 2021-2026 ($ millions)
Figure 75. Manufacturing Cost Structure Analysis of VLP-based Vaccine in 2026
Figure 76. Manufacturing Process Analysis of VLP-based Vaccine
Figure 77. Industry Chain Structure of VLP-based Vaccine
Figure 78. Channels of Distribution
Figure 79. Global VLP-based Vaccine Sales Market Forecast by Region (2027-2032)
Figure 80. Global VLP-based Vaccine Revenue Market Share Forecast by Region (2027-2032)
Figure 81. Global VLP-based Vaccine Sales Market Share Forecast by Type (2027-2032)
Figure 82. Global VLP-based Vaccine Revenue Market Share Forecast by Type (2027-2032)
Figure 83. Global VLP-based Vaccine Sales Market Share Forecast by Application (2027-2032)
Figure 84. Global VLP-based Vaccine Revenue Market Share Forecast by Application (2027-2032)
More Publications
Global Breathing Machines Market Growth 2025-2031
US$ 3,660.00
January 2025
126 pages
Global Hatching Pipettes Market Growth 2026-2032
US$ 3,660.00
October 2026
92 pages
Global Arterial Closure Devices Market Growth 2023-2029
US$ 3,660.00
February 2023
100 pages
Global Multiparametric POCT Analyzer Market Growth 2024-2030
US$ 3,660.00
June 2024
110 pages
Global Biopharmaceutical Aggregation Analysis System Market Growth 2023-2029
US$ 3,660.00
February 2023
91 pages
